The Directors (together with their families and their family trusts and pension scheme and other arrangements) in aggregate hold 1,276,379 ordinary shares in the Company, representing 2.23% of the Company’s current issued share capital. 2.23% of the issued share capital is not in public hands. The Company has been made aware of the following significant (3% or greater) shareholdings in the Company’s ordinary shares:

Number of ordinary shares % of issued share capital
Octopus Investments Nominees Ltd 5.89%
Rosetta Capital VI GP LP, on behalf of Rosetta Capital VI, LP 5.65%
Arthurian Life Sciences SPV GP Ltd, as GP of The Wales Life Sciences Investment Fund LP 5.27%

The above information was last updated on Tuesday 19 December 2023.